Checkpoint Inhibitors Market By Drug Type (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Hodgkin Lymphoma, Melanoma, Others), & By Region - Global Industry Analysis, Share, Size, Growth, Trends, And Forecasts (2018-2023)

Checkpoint Inhibitors Market By Drug Type (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Hodgkin Lymphoma, Melanoma, Others), & By Region - Global Industry Analysis, Share, Size, Growth, Trends, And Forecasts (2018-2023)

ID: 2177 | Pages: 175 | October 2018 | Region: Global


Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.

Global Checkpoint Inhibitors Market was worth USD 10.02 billion in 2018 and is expected to reach USD 34.97 billion by 2023 with a CAGR of 28.4 %.

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.

Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others. Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.

Geographically, market is further segmented into Asia-Pacific, Europe, Latin America, Middle east and Africa and North America. North America dominates the global market owing the relatively high clinical trials and funding available in this region. Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.

Some of the key players in the checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Global Checkpoint Inhibitors Market By Region, From 2018-2023 ( USD Billion )
  2. Global Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  3. Global PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  4. Global PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  5. Global CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  6. Global Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  7. Global Others Market By Region, From 2018-2023 ( USD Billion )
  8. Global Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  9. Global Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  10. Global Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  11. Global Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  12. Global Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  13. Global Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  14. Global Melanoma Market By Region, From 2018-2023 ( USD Billion )
  15. Global Others Market By Region, From 2018-2023 ( USD Billion )
  16. North America Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  17. North America PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  18. North America PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  19. North America CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  20. North America Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  21. North America Others Market By Region, From 2018-2023 ( USD Billion )
  22. North America Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  23. North America Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  24. North America Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  25. North America Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  26. North America Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  27. North America Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  28. North America Melanoma Market By Region, From 2018-2023 ( USD Billion )
  29. North America Others Market By Region, From 2018-2023 ( USD Billion )
  30. United States Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  31. United States Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  32. Canada Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  33. Canada Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  34. Europe Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  35. Europe PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  36. Europe PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  37. Europe CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  38. Europe Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  39. Europe Others Market By Region, From 2018-2023 ( USD Billion )
  40. Europe Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  41. Europe Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  42. Europe Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  43. Europe Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  44. Europe Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  45. Europe Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  46. Europe Melanoma Market By Region, From 2018-2023 ( USD Billion )
  47. Europe Others Market By Region, From 2018-2023 ( USD Billion )
  48. U.K. Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  49. U.K. Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  50. Germany Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  51. Germany Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  52. France Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  53. France Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  54. Italy Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  55. Italy Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  56. Spain Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  57. Spain Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  58. Asia-Pacific Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  59. Asia-Pacific PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  60. Asia-Pacific PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  61. Asia-Pacific CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  62. Asia-Pacific Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  63. Asia-Pacific Others Market By Region, From 2018-2023 ( USD Billion )
  64. Asia-Pacific Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  65. Asia-Pacific Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  66. Asia-Pacific Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  67. Asia-Pacific Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  68. Asia-Pacific Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  69. Asia-Pacific Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  70. Asia-Pacific Melanoma Market By Region, From 2018-2023 ( USD Billion )
  71. Asia-Pacific Others Market By Region, From 2018-2023 ( USD Billion )
  72. Japan Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  73. Japan Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  74. China Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  75. China Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  76. India Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  77. India Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  78. Australia Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  79. Australia Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  80. South Korea Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  81. South Korea Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  82. Latin America Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  83. Latin America PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  84. Latin America PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  85. Latin America CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  86. Latin America Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  87. Latin America Others Market By Region, From 2018-2023 ( USD Billion )
  88. Latin America Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  89. Latin America Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  90. Latin America Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  91. Latin America Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  92. Latin America Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  93. Latin America Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  94. Latin America Melanoma Market By Region, From 2018-2023 ( USD Billion )
  95. Latin America Others Market By Region, From 2018-2023 ( USD Billion )
  96. Brazil Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  97. Brazil Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  98. Argentina Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  99. Argentina Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  100. Mexico Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  101. Mexico Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  102. Rest of Latin America Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  103. Rest of Latin America Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  104. Middle East & Africa Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  105. Middle East & Africa PD-1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  106. Middle East & Africa PD-L1 inhibitors Market By Region, From 2018-2023 ( USD Billion )
  107. Middle East & Africa CTLA-4 Market By Region, From 2018-2023 ( USD Billion )
  108. Middle East & Africa Chimeric Antigen Receptor T-cell Market By Region, From 2018-2023 ( USD Billion )
  109. Middle East & Africa Others Market By Region, From 2018-2023 ( USD Billion )
  110. Middle East & Africa Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  111. Middle East & Africa Lung cancer Market By Region, From 2018-2023 ( USD Billion )
  112. Middle East & Africa Renal cancer Market By Region, From 2018-2023 ( USD Billion )
  113. Middle East & Africa Blood cancer Market By Region, From 2018-2023 ( USD Billion )
  114. Middle East & Africa Bladder Cancer Market By Region, From 2018-2023 ( USD Billion )
  115. Middle East & Africa Hodgkin lymphoma Market By Region, From 2018-2023 ( USD Billion )
  116. Middle East & Africa Melanoma Market By Region, From 2018-2023 ( USD Billion )
  117. Middle East & Africa Others Market By Region, From 2018-2023 ( USD Billion )
  118. Middle East Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  119. Middle East Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
  120. Africa Checkpoint Inhibitors Market By Drug Type, From 2018-2023 ( USD Billion )
  121. Africa Checkpoint Inhibitors Market By Application, From 2018-2023 ( USD Billion )
Middle East And Africa Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Ov...
Latin America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Asia-pacific Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive B...
Europe Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder...
North America Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive ...
Overactive Bladder Treatment Market By Treatment (Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation), By Disease (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder) And B...
Middle East And Africa Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Lab...
Latin America Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories...
Asia-Pacific Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories,...
Europe Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospital Laboratories, Refer...
North-America Blood Culture Tests Market By Method (Automated, Manual), Product (Consumables, Instrument), Technology (Culture-based, PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia), End User (Hospit...
Blood Culture Tests Market By Product Type (Gait Belts & Lift Vests, Canes, Crutches, Walker, Wheelchairs, Power Scooters), And Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-202...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.